← FDA DRUG APPROVALS

FDA ANDA · ANDA213859

ESOMEPRAZOLE MAGNESIUM

Sponsor: GUANGZHOU NOVAKEN

APPLICATION
ANDA213859
TYPE
ANDA
ORIGINAL APPROVAL
2020-11-18
LATEST ACTION
2024-07-17
ROUTE
ORAL
DOSAGE FORM
CAPSULE, DELAYED REL PELLETS
MARKETING STATUS
Prescription

Products

ESOMEPRAZOLE MAGNESIUMPrescription
ESOMEPRAZOLE MAGNESIUM EQ 40MG BASE · CAPSULE, DELAYED REL PELLETS · ORAL
ESOMEPRAZOLE MAGNESIUMPrescription
ESOMEPRAZOLE MAGNESIUM EQ 20MG BASE · CAPSULE, DELAYED REL PELLETS · ORAL

Approval history

2024-07-17Labeling · Supplement 7 · standardAP
2024-07-17Labeling · Supplement 10 · standardAP
2022-01-13Labeling · Supplement 1 · standardAP
2020-11-18UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →